Praxis: Moving To Strong Buy Based On Ulixacaltamide Success In Treating ET [Seeking Alpha]
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: Seeking Alpha
PRAX's Ulixacaltamide achieved primary endpoints in two phase 3 studies, positioning it as the first potential FDA-approved therapy for Essential Tremor, targeting a large unmet market. Upcoming PRAX catalysts include a pre-NDA meeting with the FDA in Q4 2025 and a potential NDA filing for Ulixacaltamide in 2026, alongside advancing late-stage trials for Vormatrigine and Relutrigine. With a strengthened cash position and multiple late-stage programs, PRAX is well-funded to reach key milestones, though regulatory and clinical risks remain. Shinsei Motions/iStock via Getty Images The last time I spoke about Praxis Precision Medicines, Inc. PRAX ) it was in a Seeking Alpha article entitled "Positive 8-Week Radiant Study Data Leads To Other Expected Catalysts." In essence, I spoke about More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026 [Seeking Alpha]Seeking Alpha
- Top Midday Gainers [Yahoo! Finance]Yahoo! Finance
- Praxis Precision Medicines (NASDAQ:PRAX) was given a new $304.00 price target on by analysts at Needham & Company LLC.MarketBeat
- Praxis Precision Medicines (NASDAQ:PRAX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.MarketBeat
PRAX
Earnings
- 11/5/25 - Beat
PRAX
Sec Filings
- 11/21/25 - Form 4
- 11/21/25 - Form 4
- 11/21/25 - Form 4
- PRAX's page on the SEC website